01-31280. Manufacturer of Controlled Substances; Notice of Application  

  • Start Preamble

    Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 17, 2001, Cerilliant Corporation, 14050 Summit Drive #121, P.O. Box 201088, Austin, Texas 78708-0189, made application by renewal to the Drug Enforcement Administration (DEA) for registration as bulk manufacturer of the basic classes of controlled substances listed below:

    DrugSchedule
    Cathinone (1235)I
    Methcathinone (1237)I
    N-Ethylamphetamine (1475)I
    N, N-Dimethylamphetamine (1480)I
    Aminorex (1585)I
    4-Methylaminorex (cis isomer) (1590)I
    Gamma hydroxybutyric acid (2010)I
    Methaqualone (2565)I
    Alpha-Ethyltryptamine (7249)I
    Lysergic acid diethylamide (7315)I
    Tetrahydrocannabinols (7370)I
    Mescaline (7381)I
    3, 4, 5-Trimethoxyamphetamine (7390)I
    4-Bromo-2, 5-dimethoxyaphetamine (7391)I
    4-Bromo-2, 5-dimethoxphenethylamine (7392)I
    4-Methyl-2, 5-dimethoxyamphetamine (7395)I
    2, 5-Dimethoxyamphetamine (7396)I
    2, 5-Dimethoxy-4-ethylamphetamie (7399)I
    3, 4-Methylenedioxyamphetamine (7400)I
    5-Methoxy-3, 4-methylenedioxyamphetamine (7401)I
    N-Hydroxy-3, 4-methylenedioxyamphetamine (7402)I
    3, 4-Methylenedioxy-N-ethylamphetamine (7404)I
    3, 4-Methylenedioxymethamphetamine (7405)I
    4-Methoxyamphetamine (7411)I
    Start Printed Page 65745
    Bufotenine (7433)I
    Diethyltryptamine (7434)I
    Dimethyltryptamine (7435)I
    Psilocybin (7437)I
    Psilocyn (7438)I
    Acetyldihydrocodeine (9051)I
    Benzylmorphine (9052)I
    Codeine-N-oxide (9053)I
    Dihydromorphine (9145)I
    Heroin (9200)I
    Hydromorphinol (9301)I
    Methyldihydromorphine (9304)I
    Morphone-N-oxide (9307)I
    Normorphine (9313)I
    Pholcodine (9314)I
    Acetylmethadol (9601)I
    Allyprodine (9602)I
    Alphacetylmethadol except Levo-Alphacetylmethadol (9603)I
    Alphameprodine (9604)I
    Alphamethadol (9605)I
    Betacetylmethadol (9607)I
    Betameprodine (9608)I
    Betamethadol (9609)I
    Betaprodine (9611)I
    Hydromorphinol (9627)I
    Noracymethadol (9633)I
    Norlevorphanol (9634)I
    Normethadone (9635)I
    Trimeperidine (9646)I
    Phenomorphan (9647)I
    Para-Fluorofentanyl (9812)I
    3-Methylfentanyl (9813)I
    Alpha-methylfentanyl (9814)I
    Acetyl-alpha-methylfentanyl (9815)I
    Beta-hydroxyfentanyl (9830)I
    Beta-hydroxy-3-methylfentanyl (9831)I
    Alpha-Methylthiofentianyl (9832)I
    3-Methylthiofentanyl (9833)I
    Thiofentanyl (9835)I
    Amphetamine (1100)II
    Methamphetamine (1105)II
    Phenmetrazine (1631)II
    Methylphenidate (1724)II
    Amobarbital (2125)II
    Pentobarbital (2270)II
    Secobarbital (2315)II
    Glutethimide (2550)II
    Nabilone (7379)II
    1-Phenylcyclohexylamine (7460)II
    Phencyclidine (7471)II
    1-Piperidinocyclohexanecarbonitrile (8603)II
    Alphaprodine (9010)II
    Cocaine (9041)II
    Codeine (9050)II
    Dihydrocodeine (9220)II
    Oxycodone (9143)II
    Hydromorphone (9150)II
    DIphenoxylate (9170)II
    Benzoylecgonine (9180)II
    Ethylmorphine (9190)II
    Hydrocodone (9193)II
    Levomethorphan (9210)II
    Levorphanol (9200)II
    Isomethadone (9226)II
    Meperidine (9230)II
    Methadone (9250)II
    Methadone-intermediate (9254)II
    Dextropropoxyphene, bulk (non-dosage forms) (9273)II
    Morphine (9300)II
    Thebaine (9333)II
    Levo-alphacetylmethadol (9648)II
    Oxymorphone (9652)II
    Noroxymorphone (9668)II
    Racemethorphane (9732)II
    Start Printed Page 65746
    Alfentanil (9737)II
    Sufentanil (9740)II
    Fentanyl (9801)II

    The firm plans to manufacture small quantities of the listed controlled substances to make deuterated and non-deuterated drug reference standards which will be distributed to analytical and forensic laboratories for drug testing programs.

    Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

    Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistance Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than February 19, 2002.

    Start Signature

    Dated: November 16, 2001.

    Laura M. Nagel,

    Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

    End Signature End Preamble

    [FR Doc. 01-31280 Filed 12-19-01; 8:45 am]

    BILLING CODE 4410-09-M

Document Information

Published:
12/20/2001
Department:
Drug Enforcement Administration
Entry Type:
Notice
Document Number:
01-31280
Pages:
65744-65746 (3 pages)
PDF File:
01-31280.pdf